IMNM

Immunome (IMNM)

Immunome Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMNM

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/27	21 : 00	Business Wire	Immunome Appoints Phil Tsai as Chief Technical Officer	NASDAQ:IMNM	Immunome Inc
2024/06/19	10 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/06/19	10 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/06/19	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/06/19	09 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/06/19	09 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/06/14	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNM	Immunome Inc
2024/05/20	21 : 00	Business Wire	Immunome Announces Completion of Purchase of Assets from Atreca	NASDAQ:IMNM	Immunome Inc
2024/05/18	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/05/17	21 : 00	Business Wire	Immunome Announces Promotion of Max Rosett to Chief Financial Officer	NASDAQ:IMNM	Immunome Inc
2024/05/14	21 : 48	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMNM	Immunome Inc
2024/05/14	21 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMNM	Immunome Inc
2024/05/14	21 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNM	Immunome Inc
2024/05/14	21 : 00	Business Wire	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:IMNM	Immunome Inc
2024/05/08	21 : 00	Business Wire	Immunome to Present at 2024 Bank of America Healthcare Conference	NASDAQ:IMNM	Immunome Inc
2024/05/02	21 : 00	Business Wire	Immunome Appoints Kinney Horn as Chief Business Officer	NASDAQ:IMNM	Immunome Inc
2024/04/25	21 : 26	Business Wire	Immunome Appoints Sandra M. Swain to Board of Directors	NASDAQ:IMNM	Immunome Inc
2024/04/05	21 : 00	Business Wire	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting	NASDAQ:IMNM	Immunome Inc
2024/03/29	05 : 02	Business Wire	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets	NASDAQ:IMNM	Immunome Inc
2024/03/26	21 : 00	Business Wire	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala	NASDAQ:IMNM	Immunome Inc
2024/03/07	22 : 00	Business Wire	Immunome to Participate in the Leerink Partners Global Biopharma Conference	NASDAQ:IMNM	Immunome Inc
2024/03/01	22 : 00	Business Wire	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	NASDAQ:IMNM	Immunome Inc
2024/02/22	11 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/02/22	11 : 07	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMNM	Immunome Inc
2024/02/20	22 : 15	Business Wire	Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	NASDAQ:IMNM	Immunome Inc
2024/02/17	06 : 05	Business Wire	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:IMNM	Immunome Inc
2024/02/15	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMNM	Immunome Inc
2024/02/15	06 : 09	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMNM	Immunome Inc
2024/02/14	12 : 38	Business Wire	Immunome Announces Pricing of Public Offering of Common Stock	NASDAQ:IMNM	Immunome Inc
2024/02/14	06 : 36	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMNM	Immunome Inc